Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.
about
Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.A review of infectious complications after haploidentical hematopoietic stem cell transplantations.Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms-Where Are We Today?Incidence and clinical profile of tuberculosis after allogeneic stem cell transplantation.Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).Vaccination of allogeneic hematopoietic stem cell transplant recipients-what should be considered?Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioned Autologous Stem Cell Transplantation.Waterhouse-Friderichsen syndrome due to Neisseria meningitidis infection in a young adult with thrombotic microangiopathy and eculizumab treatment: case report and review of management.Consensus statement for cancer patients requiring intensive care support.Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).Continuous Decline of Seroprevalence in Hospital: A 1997-2014 Longitudinal Study in Paris, France
P2860
Q38751500-5D2B6AA7-8652-4C16-9B3B-EB407AA490E9Q39196770-F917BFC7-A7FB-4397-A201-ADEC4B414411Q39247468-FC1A8683-697F-4F34-BF34-CEDC805206B3Q40041299-D7826492-164A-4AE2-AAA7-AE75DB78CECEQ47709323-7061A5B9-2885-4CA9-AEE7-7E1199D80D34Q48138642-B89D8F58-646D-4547-B2A0-7BC34CC5B748Q48155956-831B1A01-F6D2-4EA3-BBE2-31AB2842EFE8Q48342532-29645DD5-31F7-46E7-9B43-C59D0F41D1A7Q52572831-FD4FFB8F-BF38-4909-9C6C-814E6CA16D45Q54432568-E18473B8-C262-4058-83DC-417A73C079A0Q55049916-23F49782-F3CB-4F31-A3B2-BBBC853D4507Q55364518-18DFCD25-E3CA-4B84-BCE1-2110BBCBFD21Q57817957-19727561-2FA0-465A-A0D4-F0019AE69C6F
P2860
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Infectious diseases in allogen ...... axis strategy guidelines 2016.
@en
Infectious diseases in allogen ...... axis strategy guidelines 2016.
@nl
type
label
Infectious diseases in allogen ...... axis strategy guidelines 2016.
@en
Infectious diseases in allogen ...... axis strategy guidelines 2016.
@nl
prefLabel
Infectious diseases in allogen ...... axis strategy guidelines 2016.
@en
Infectious diseases in allogen ...... axis strategy guidelines 2016.
@nl
P2093
P2860
P1433
P1476
Infectious diseases in allogen ...... axis strategy guidelines 2016.
@en
P2093
Andrew J Ullmann
Georg Maschmeyer
Gerda Silling
Hartmut Bertz
Infectious Diseases Working Pa ...... od and Marrow Transplantation)
Jörg Janne Vehreschild
Martin Schmidt-Hieber
Michael Kiehl
Olaf Penack
Sabine Mousset
P2860
P304
P356
10.1007/S00277-016-2711-1
P577
2016-06-24T00:00:00Z